Company Encyclopedia
View More
name
Goto Biopharm
300966.SZ
Hubei Goto Biopharm Co.,Ltd. engages in the research, development, production, and sale of steroid drug raw materials and intermediates in China and internationally. It offers starting materials, such as androstenedione, bisnordiol, and 9-hydroxyandrostenedione; intermediates, including sex hormone, progesterone, corticosteroid, and other pharmaceutical raw materials. The company was founded in 2006 and is based in Xiangyang, China.
1.568 T
300966.SZMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking79/80
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-5.07%D
    • Profit Margin-7.32%D
    • Gross Margin13.99%D
  • Growth ScoreC
    • Revenue YoY14.55%B
    • Net Profit YoY-228.97%E
    • Total Assets YoY5.91%B
    • Net Assets YoY-7.13%D
  • Cash ScoreC
    • Cash Flow Margin-1365.52%E
    • OCF YoY14.55%B
  • Operating ScoreD
    • Turnover0.23D
  • Debt ScoreD
    • Gearing Ratio66.47%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Goto Biopharm: Cumulatively repurchased 0.17% of the company's shares

    Goto Biopharm announced that as of August 31, 2025, the company has repurchased a total of 197,500 shares through a dedicated securities account for share repurchase via centralized bidding, accounting for 0.17% of the company's current total share capital, with a highest transaction price of 16.05 yuan/share and a lowest transaction price of 13.15 yuan/share, for a total transaction amount of 3.0299 million yuan. This repurchase complies with relevant laws and regulations and the company's share repurchase plan, and the company will continue to implement the repurchase plan within the repurchase period and fulfill its information disclosure obligations in a timely manner

    Zhitong·
    SZ
    300966
    -5.51%
    Zhitong·
    SZ
    300966
    -5.51%

    Goto Biopharm: Net profit loss of 11.1525 million yuan in the first half of 2025, a decrease of 117.88%

    Goto Biopharm announced that in the first half of 2025, operating revenue was 302 million yuan, a year-on-year increase of 29.33%. The net profit loss was 11.1525 million yuan, a decrease of 117.88%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into share capital

    Zhitong·
    SZ
    300966
    -5.51%
    Zhitong·
    SZ
    300966
    -5.51%

    Goto Biopharm's subsidiary plans to purchase assets required for production and operation from YuanKe Biotechnology for no more than RMB 16.5703 million

    Goto Biopharm's wholly-owned subsidiary, Hubei Goto Biotechnology Co., Ltd., intends to purchase land and attachments necessary for production and operation from Hubei Yuanke Biomedical Technology Co., Ltd., with a transaction amount not exceeding 16.5703 million yuan. The asset will be used for projects such as the construction of a sewage treatment facility and Class A workshops. The two parties will sign a transfer agreement after completing the approval procedures

    Zhitong·
    SZ
    300966
    -5.51%
    Zhitong·
    SZ
    300966
    -5.51%

    The infant and assisted reproduction concepts continue to be strong, with Sunshine Dairy and other stocks hitting the limit up

    In the morning session, the baby and child, as well as assisted reproduction concepts continued to be strong, with Sunshine Dairy and Anzheng Fashion achieving three consecutive trading limits. Goto Biopharm and HSGC hit the daily limit, while DAJIAWEIKANG, Beingmate, Jinma Amusement, and Qianyuan Pharmaceutical saw significant gains

    Zhitong·
    SZ
    001318
    -3.31%
    SZ
    301126
    -4.92%
    SZ
    002570
    -2.75%
    Zhitong·
    SZ
    001318
    -3.31%
    SZ
    301126
    -4.92%
    SZ
    002570
    -2.75%

    Goto Biopharm released its first-quarter performance, with a net profit attributable to the parent company of 1.0821 million yuan, a decrease of 69.50%

    According to the Zhitong Finance APP, Goto Biopharm released its first-quarter report for 2025, with operating revenue of 139 million yuan, a year-on-year increase of 13.90%. The net profit attributable to shareholders of the listed company was 1.0821 million yuan, a year-on-year decrease of 69.50%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.3366 million yuan, a year-on-year decrease of 61.42%. The basic earnings per share were 0.01 yuan

    Zhitong·
    SZ
    300966
    -5.51%
    Zhitong·
    SZ
    300966
    -5.51%